Correlation and clinical significance of placental tissue selectin (E), angiotensin II and its receptors, and oxidized lipid levels in patients with preeclampsia
Preeclampsia: Placental Selectin, Angiotensin II, and Oxidized Lipids
Abstract
Background: The purpose was to analyze the levels of placental tissue selectins (E), angiotensin II (AngII) and its receptors (ATRs), and oxidized lipids (malondialdehyde (MDA), 8-isoprostane 2a) in patients with preeclampsia (PE). (8-iso-PGF2a)) correlation and clinical significance.
Methods: Select 30 PE pregnant women who were admitted to our hospital from March 2023 to January 2024 as the case group, and select another 30 normal pregnant women who were registered in our hospital during the same period as the health group .The general information of the two groups and placental tissue selectin (E), plasma AngII, ATRs, placental tissue MDA, 8-iso-PGF2a and blood pressure levels (systolic blood pressure (SBP), diastolic blood pressure (DBP)) were compared. Pearson correlation was used to analyze the correlation between the expression of selectin (E), AngII, ATRs, MDA, 8-iso-PGF2a and the levels of SBP and DBP. Linear regression analysis was used to analyze the correlation between the expression of selectin (E), AngII, ATRs, MDA, 8-iso-PGF2a, SBP, DBP and other indicators and the occurrence of PE. ROC curves were drawn to analyze the value of placental tissue selectin (E), AngII, ATRs, MDA, and 8-iso-PGF2a individually and jointly in predicting the risk of PE.
Results The expression of placental tissue selectin (E), AngII, ATRs, MDA, 8-iso-PGF2a and the levels of SBP and DBP in the case group were higher than those in the healthy group (P<0.05). Pearson correlation showed that the expression levels of placental tissue selectin (E), AngII, ATRs, MDA, and 8-iso-PGF2a were positively correlated with SBP and DBP (r>0, P<0.05). Linear regression analysis showed that placental tissue selectin (E), AngII, ATRs, MDA, 8-iso-PGF2a expression and SBP, DBP levels were closely related to the occurrence of PE (P<0.05). The results of drawing the ROC curve showed that the AUCs of placental tissue selectin (E), AngII, ATRs, MDA, and 8-iso-PGF2a expression in predicting the occurrence of PE were 0.854, 0.756, 0.745, 0.885, 0.900, and 0.905 respectively.
Conclusion Placenta tissue selectin (E), AngII, ATRs, MDA, and 8-iso-PGF2a are highly expressed in pregnant women with PE. The expression of the above indicators is related to maternal blood pressure levels and the occurrence of PE, and their combination can effectively increase predictive value of the risk of PE.
References
2. Ives CW, Sinkey R, Rajapreyar I, Tita A, Oparil S. Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 76(14): 1690-702.
3. Vargas VR, Varela MJ, Fajardo BE. Renin-angiotensin system: Basic and clinical aspects-A general perspective. Endocrinol Diab Nutr 2022; 69(1): 52-62.
4. Biwer LA, Lu Q, Ibarrola J, Stepanian A, Man JJ, Carvajal BV, et al. Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia. Circ Res 2023; 132(6): 674-89.
5. Civieri G, Iop L, Tona F. Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies. Int J Mol Sci 2022; 23(2): 927.
6. Han Q, Zheng S, Chen R, Zhang H, Yan J. A New Model for the Predicting the Risk of Preeclampsia in Twin Pregnancy. Front Physiol 2022; 13: 850149.
7. Marin R, Chiarello DI, Abad C, Rojas D, Toledo F, Sobrevia L. Oxidative stress and mitochondrial dysfunction in early-onset and late-onset preeclampsia. Bba-Mol Basis Dis 2020; 1866(12): 165961.
8. Cabunac P, Karadzov ON, Ardalic D, Banjac G, Ivanisevic J, Janac J, et al. Unraveling the role of oxidative stress and lipid status parameters in the onset of preeclampsia. Hypertens Pregnancy 2021; 40(2): 162-70.
9. Wang Y, Li B, Zhao Y. Inflammation in Preeclampsia: Genetic Biomarkers, Mechanisms, and Therapeutic Strategies. Front Immunol 2022; 13: 883404.
10. Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ Res 2019; 124(7): 1094-112.
11. Tomimatsu T, Mimura K, Matsuzaki S, Endo M, Kumasawa K, Kimura T. Preeclampsia: Maternal Systemic Vascular Disorder Caused by Generalized Endothelial Dysfunction Due to Placental Antiangiogenic Factors. Int J Mol Sci 2019; 20(17): 4246.
12. Jena MK, Sharma NR, Petitt M, Maulik D, Nayak NR. Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. Biomolecules 2020; 10(6): 953.
13. Skrzypczyk P, Ozimek A, Ofiara A, Szyszka M, Soltyski J, Stelmaszczyk-Emmel A, et al. Markers of endothelial injury and subclinical inflammation in children and adolescents with primary hypertension. Cent Eur J Immunol 2019; 44(3): 253-61.
14. Saez T, Spaans F, Kirschenman R, Sawamura T, Davidge ST. High-cholesterol diet during pregnancy induces maternal vascular dysfunction in mice: potential role for oxidized LDL-induced LOX-1 and AT1 receptor activation. Clin Sci 2020; 134(17): 2295-313.
15. Yu Y, Zhang L, Xu G, Wu Z, Li Q, Gu Y, et al. Angiotensin II Type I Receptor Agonistic Autoantibody Induces Podocyte Injury via Activation of the TRPC6- Calcium/Calcineurin Pathway in Pre-Eclampsia. Kidney Blood Press R 2018; 43(5): 1666-76.
16. Mentese A, Guven S, Demir S, Sumer A, Yaman SO, Alver A, et al. Circulating parameters of oxidative stress and hypoxia in normal pregnancy and HELLP syndrome. Adv Clin Exp Med 2018; 27(11): 1567-72.
17. Mazloomi S, Alimohammadi S, Khodadadi I, Ghiasvand T, Shafiee G. Evaluation of methylenetetrahydrofolate reductase (MTHFR) activity and the levels of homocysteine and malondialdehyde (MDA) in the serum of women with preeclampsia. Clin Exp Hypertens 2020; 42(7): 590-4.
18. Chiarello DI, Abad C, Rojas D, Toledo F, Vazquez CM, Mate A, et al. Oxidative stress: Normal pregnancy versus preeclampsia. Bba-Mol Basis Dis 2020; 1866(2): 165354.
Copyright (c) 2024 Yan Gao, Guohong Wu, Haiting Huang, Xiaoyan Lu, Peifen Wu, Suiyi Zou, Zhenyan Liu

This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
